InMode, Daktronics, Dominos Pizza And Other Big Stocks Moving ... - Investing.com UK

CNTA Stock  USD 17.18  0.14  0.82%   
About 51% of Centessa Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that many traders are impartial. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
InMode, Daktronics, Dominos Pizza And Other Big Stocks Moving ... Investing.com UK

Read at news.google.com
Google News at Macroaxis
  

Centessa Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Centessa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Centessa Pharmaceuticals Fundamental Analysis

We analyze Centessa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Centessa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Centessa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Centessa Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Centessa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Centessa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Centessa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Centessa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Centessa Pharmaceuticals Related Equities

CCCCC4 Therapeutics   9.28   
0%
94.0%
IRONDisc Medicine   4.35   
0%
44.0%
STROSutro Biopharma   4.26   
0%
43.0%
DSGNDesign Therapeutics   4.23   
0%
42.0%
TARSTarsus Pharmaceuticals   2.94   
0%
29.0%
EWTXEdgewise Therapeutics   1.15   
0%
11.0%
HLVXHillevax   1.02   
0%
10.0%
CRNXCrinetics Pharmaceuticals   0.97   
0%
9.0%
NAMSWNewAmsterdam Pharma   0.21   
2.0%
0%
CGEMCullinan Oncology   0.24   
2.0%
0%
ERASErasca   0.67   
6.0%
0%
NUVLNuvalent   1.01   
10.0%
0%
MLYSMineralys Therapeutics,   1.45   
14.0%
0%
GNFTGenfit   2.79   
28.0%
0%
LRMRLarimar Therapeutics   2.81   
28.0%
0%
TRDAEntrada Therapeutics   2.97   
30.0%
0%
OPTOpthea   3.32   
33.0%
0%
IPSCCentury Therapeutics   4.08   
41.0%
0%
GLUEMonte Rosa   9.85   
100.0%
0%

Complementary Tools for Centessa Stock analysis

When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
CEOs Directory
Screen CEOs from public companies around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals